The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| APLT | -91.01% | -94.04% | -43.11% | -90% |
| S&P | +14.08% | +93.57% | +14.12% | +142% |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$0.11M | -595.5% |
| Gross Margin | 14.75% | 0.0% |
| Market Cap | $44.04M | -91.7% |
| Market Cap / Employee | $1.26M | 0.0% |
| Employees | 35 | 0.0% |
| Net Income | -$21.33M | -836.0% |
| EBITDA | -$22.99M | -13.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $30.42M | -75.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.16M | 7083.3% |
| Short Term Debt | $0.45M | 141.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -82.05% | 0.0% |
| Return On Invested Capital | -285.53% | -9.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.34M | 10.0% |
| Operating Free Cash Flow | -$20.34M | 10.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 13.48 | 16.91 | 9.65 | 1.20 | -101.79% |
| Price to Sales | 251.80 | 266.12 | 369.98 | - | |
| Price to Tangible Book Value | 13.48 | 16.91 | 9.65 | 1.20 | -101.79% |
| Enterprise Value to EBITDA | -38.13 | -1.16 | -0.89 | -0.75 | -97.40% |
| Return on Equity | -83.7% | -150.8% | - | ||
| Total Debt | $1.97M | $2.80M | $2.70M | $2.60M | 1110.23% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
